Reported about 16 hours ago
Eli Lilly's shares fell 8% after the company forecasted fourth-quarter sales for its weight-loss drug Zepbound below expectations, marking a second disappointing sales report since the drug's late 2023 launch. The company anticipates $3.5 billion in sales for Mounjaro and $1.9 billion for Zepbound, both below analysts' predictions. Lilly is also looking to expand Mounjaro into new markets like China and India in 2025, as analysts express concern about demand for incretin-based drugs.
Source: YAHOO